Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) said on Wednesday that it has entered into a new contract with an undisclosed APAC country for the supply of 350,000 doses of its non-replicating JYNNEOS smallpox/monkeypox vaccine.
Deliveries and all revenues under this contract will occur in 2023.
This latest order follows an initial order with the same country for supply in 2022.
Paul Chaplin, president and CEO of Bavarian Nordic, said in a statement: "While governments and health authorities around the world are busy fighting the current monkeypox outbreak we applaud those governments thinking beyond the current situation and building stockpiles to secure future preparedness and we are proud to assist our customers in both efforts."
With this order, together with previously announced orders from the US, Canada and other countries, Bavarian Nordic said that it now has significant orders of smallpox/monkeypox vaccines.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax